BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs FRANKLIN LAKES, N.J., July 23, 2025 / Biotech Newswire / -- BD (Becton, Dickinson ...

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, ...

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with ...

An expert discusses how home administration of oncology drugs in the US faces significant logistical and reimbursement ...

The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.

Patna: In order to improve family planning in the state, the govt decided to provide MPA-Subcutaneous, a form of injection, which is effective in cont.

While Rosie O’Donnell, 63, made a name for herself as a Broadway star and host of the Emmy-winning talk show The Rosie ...

In July 2025, CSL Behring conducted a study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after ...

KalVista Pharmaceuticals faces a shrinking HAE market, tough competition, and launch uncertainty despite FDA approval. Read ...

BD (NYSE:BDX) today announced the first pharma-sponsored combination product clinical trial using its wearable injector ...

Rezpegaldesleukin targets the interleukin-2 receptor complex in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells.

The opinion is based on positive data from the phase 3 Balance study, which showed a significant reduction of triglycerides ...